Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF)

Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: d4707c3e9bf42569b420c466c82edec4507d4468
First added on: Feb 18, 2025